Literature DB >> 3318304

New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency.

C A Stanley1.   

Abstract

There are now nine inherited diseases that have been identified in the pathway of mitochondrial fatty acid oxidation, including LCAD, MCAD, SCAD, and HMG-CoA lyase deficiencies, two forms each of CPT and MAD deficiencies and an incompletely characterized disorder of primary carnitine deficiency. The varied range of clinical manifestations in this new group of diseases should attract the attention not only of general pediatricians (coma, hypoglycemia) but also of pediatric subspecialists in neurology (myopathy), cardiology (cardiomyopathy), and gastroenterology (fatty liver), as well as genetics and metabolism. The presenting features of the genetic defects in fatty acid oxidation fit well with the concept that fatty acid oxidation plays a major role in energy production during prolonged fasting and in working cardiac and skeletal muscle. Life-threatening episodes of coma and hypoglycemia induced by fasting are a common presenting feature in most of the fatty acid oxidation disorders (MCAD, LCAD, and HMG-CoA lyase deficiencies, the infantile form of CPT deficiency, the mild form of MAD deficiency, and in some cases of primary carnitine deficiency). The hypoglycemia in these disorders is most easily explained by the inability of affected patients to use fatty acids as a fuel as a substitute for glucose. It should be stressed, however, that the coma in these disorders may occur from direct toxic effects of fatty acids or fatty acid intermediates before plasma glucose concentrations reach hypoglycemic levels. Severe disturbances of muscle function are a feature in several of the disorders; hypertrophic cardiomyopathy and chronic skeletal muscle weakness occur in both the mild and severe forms of MAD deficiency, in primary carnitine deficiency, and in some patients with LCAD deficiency. In contrast, patients with the adult form of CPT deficiency have normal muscle strength but are prone to episodes of painful rhabdomyolysis induced by prolonged exercise. These manifestations presumably reflect the requirement of working cardiac and skeletal muscle for energy supplied from fatty acid oxidation. In two of the disorders, SCAD deficiency and the severe form of MAD deficiency, chronic CNS toxicity is a dominant feature. The severe effects on the brain in these two disorders may reflect the fact that short-chain fatty acids more readily cross the blood-brain barrier than longer-chain fatty acids.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318304

Source DB:  PubMed          Journal:  Adv Pediatr        ISSN: 0065-3101


  36 in total

1.  Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency.

Authors:  C A Stanley; F Sunaryo; D E Hale; J P Bonnefont; F Demaugre; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

Review 2.  Diagnosis and management of inborn errors of metabolism.

Authors:  J E Wraith
Journal:  Arch Dis Child       Date:  1989-10       Impact factor: 3.791

Review 3.  Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases.

Authors:  Harjot K Saini-Chohan; Ryan W Mitchell; Frédéric M Vaz; Teresa Zelinski; Grant M Hatch
Journal:  J Lipid Res       Date:  2011-11-07       Impact factor: 5.922

Review 4.  Carnitine biosynthesis in mammals.

Authors:  Frédéric M Vaz; Ronald J A Wanders
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  Carnitine deficiency with cardiomyopathy presenting as neonatal hydrops: successful response to carnitine therapy.

Authors:  P Steenhout; C Elmer; A Clercx; D Blum; D Gnat; S van Erum; F Vertongen; E Vamos
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

6.  Postperfusion energy metabolism of steatotic graft and its relation to early graft viability following liver transplantation.

Authors:  C Miki; K Iriyama; D F Mirza; A D Mayer; J A Buckels; H Suzuki; P McMaster
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

7.  Early diagnosis and treatment of neonatal medium-chain acyl-CoA dehydrogenase deficiency: report of two siblings.

Authors:  C Catzeflis; C Bachmann; D E Hale; P M Coates; U Wiesmann; J P Colombo; F Joris; G Délèze
Journal:  Eur J Pediatr       Date:  1990-05       Impact factor: 3.183

8.  Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines.

Authors:  Z Altun; Y Olgun; P Ercetin; S Aktas; G Kirkim; B Serbetcioglu; N Olgun; E A Guneri
Journal:  Cell Prolif       Date:  2013-11-29       Impact factor: 6.831

9.  Heterozygotes for plasmalemmal carnitine transporter defect are at increased risk for valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts.

Authors:  I Tein; S DiMauro; Z W Xie; D C De Vivo
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

10.  Carnitine and physical exercise.

Authors:  O J Heinonen
Journal:  Sports Med       Date:  1996-08       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.